Skip to content

Batch Fermentation and Microbiome Analysis

Evaluation of the Effect of Different Nutrients on the Gut Microbiota Composition and Metabolic Activity by Using in Vitro Batch Fermentation and Cellular Models

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06097130
Enrollment
40
Registered
2023-10-24
Start date
2020-08-18
Completion date
2025-03-26
Last updated
2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Microbiome

Brief summary

The correlation between diet and microbiota as well as the effect of microbiota on human health is well established. Studies have shown that people following specific diets have different microbiome profile compared to those following traditional or ordinary diets. In order to screen several food ingredients for their effects on human microbiota composition and metabolic activities, in vitro studies are proposed. Nutrients are added in-vitro in fecal sample, eliminating the need for participants to consume any nutritional product. The batch fermentation in vitro system simulates human colonic microbiota from fecal samples, enabling the complex mixture of microorganisms. This system could serve as a simple model to simulate the diversity as well as the metabolism of human colonic microbiota. We will evaluate the effect on nutrient/s on the age specific microbiome via an in vitro fermentation approach for the 0 to 60 year-old period.

Interventions

None listed

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
0 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy participant aged from 0 to 60 (based on medical history, physical examination and review of childhood growth chart) * Written informed consent has been obtained from the parent(s)/legally acceptable representative (LAR) of toddlers and teenagers * Written informed consent has been obtained for participants aged from 14 years old and above * Child's parent(s)/legal representative or participant is willing and able to fulfill the requirements of the study protocol. * Ability to collect their or their infant/child's fecal sample.

Exclusion criteria

* The parent(s)/legally acceptable representative (LAR) is not able to provide evidence of parental authority or legal representation. * Participant following a particular regimen of any type such as vegan, vegetarian, ketogenic, paleo diet, * Chronic or recurrent diarrhea with spontaneous bowel movements more often than 2 times daily, * Antibacterial/antifungal therapy during the 3 months prior to study enrolment, * Medications or supplements that are known to alter gut function or microbiota (i.e. acid antisecretory drugs, pre-/probiotics supplements, laxatives) during the 4 weeks prior to study enrolment, * Prior gastrointestinal surgery (apart from appendectomy, cholecystectomy or herniotomy), * Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer, * Artificially sweetened beverage intake higher than 1000 ml/ per day, * Current or history of gastrointestinal diseases like (Celiac Disease, Crohn's Disease, Ulcerative colitis, Irritable Bowel Syndrome, infantile colic, recurrent abdominal pain, functional constipation, ulcers, infections (based on anamnesis), * Participants participating in another interventional study, * Participants/parents having a hierarchical or family link with the research team members.

Design outcomes

Primary

MeasureTime frameDescription
Change in microbiota compositionThrough study completion, an average of 1 yearMeasured by 16s rRNA sequencing or next Generation Sequencing (NGS) or by qPCR

Secondary

MeasureTime frameDescription
Change in Short Chain Fatty Acids (SCFA)Through study completion, an average of 1 yearMeasured using Gas Chromatography (GC)
Change in metabolic profileThrough study completion, an average of 1 yearMeasured using Gas Chromatography (GC) or Gas chromatography-mass spectrometry (GC-MS)
Protein expression of epithelial cellsThrough study completion, an average of 1 yearMeasured by western blot

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026